超级老年人的康泰佐利德:通过药理动力学见解平衡有效性和安全性
Tingting Liu1, Beibei Liang2, Bing Liu3
1Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Clinical interventions in aging
|November 17, 2025
概括
这项研究表明,在超级老年人和健康成年人中,康特佐利德的药理动力学类似. 400毫克或800毫克每12小时的剂量是有效和安全的治疗老年患者的感染.
科学领域:
- 药理学 药理学是指药理学的学科.
- 老年医学 老年医学
- 传染性疾病 传染性疾病
背景情况:
- 氧利丁抗生素对于治疗格拉姆阳性细菌感染至关重要.
- 在超老年患者 (≥80岁) 中,康泰佐利德的药理动力学 (PK) 概况和安全性尚未得到充分确立.
- 了解这种群体中康特佐利德的行为对于优化治疗策略至关重要.
研究的目的:
- 在超老年患者中评估康泰佐利德的药理动力学特征.
- 评估这个人口群体中康特佐利德的安全性和耐受性.
- 在超级老年人中确定康特佐利德的最佳剂量方案.
主要方法:
- 进行了一项涉及13名超级老年患者 (平均年龄为94.9±4.8岁) 的研究.
- 在不同剂量 (400 mg q24h,400 mg q12h,800 mg q12h) 中分析了康泰佐利德的血度.
- 进行了稳定状态概况,不良事件的系统评估,并与健康成年人的数据进行了比较.
主要成果:
- 康泰佐利德显示Cmax和AUC0-t的剂量依赖性增加.
- 超老年患者在800毫克每12小时的PK参数与健康成年人相似,Tmax延长和t1/2.2.更短.
- 400毫克每小时12次的剂量在MICs ≤1 mg/L时达到>90%的PTA,而在MICs 2-4毫克/L时800毫克每小时12次是有效的.
- 与linezolid相比,contezolid耐受性很好,血小板缺血的发生率明显较低.
结论:
- 康泰佐利德在超级老年人和健康成年人中表现出类似的PKs.
- 对于MICs ≤1 mg/L的病原体,400 mg q12h的剂量足够;对于较高的MICs (2-4 mg/L),建议使用800 mg q12h.
- 这两种剂量在超级老年患者中都显示出良好的安全性.
相关概念视频
Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
213
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
213
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
226
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
226
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
221
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
221
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
188
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
188
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180


